Haisco Pharmaceutical Group: Announcement on Obtaining the Acceptance Notice for the New Indication of Innovative Drug HSK21542 Injection IND Application
Haisco Pharmaceutical Group: 2024 Interim Performance Forecast
Haisco Pharmaceutical Group: Announcement on obtaining new indications for Type 1 innovative drug Cligabalin Hydrochloride Capsules in the Drug Registration Certificate
Haisco Pharmaceutical Group: Announcement of the resolution of the 15th meeting of the 5th board of directors.
Haisco Pharmaceutical Group: Announcement Regarding Obtaining the Pharmaceutical Registration Certificate for Class 1 Innovative Drug - Carvedilol Tablets
Haisco Pharmaceutical Group: Announcement regarding the approval notice for clinical trial of innovative drug HSK42360 tablets.
Haisco Pharmaceutical Group: Announcement Regarding the Release of Pledged Shares by the Controlling Shareholder.
Haisco Pharmaceutical Group: Announcement on the Progress of Establishing a Subsidiary in Shannan City, Tibet Autonomous Region.
Haisco Pharmaceutical Group: Notice on obtaining the “Notice of Acceptance” of the IND application for the innovative drug HSK44459 tablets
Haisco Pharmaceutical Group: Notice on Obtaining the “Drug Registration Certificate” for Class 1 Innovative Drug Cligabarin Benzenesulfonate Capsules
Haisco Pharmaceutical Group: 2023 Equity Distribution Implementation Notice
Haisco Pharmaceutical Group: Legal Opinion of Beijing Zhonglun (Shenzhen) Law Firm on the 2023 Annual General Meeting of Shareholders of Hisilicon Pharmaceuticals Group Co., Ltd.
Haisco Pharmaceutical Group: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Haisco Pharmaceutical Group: Notice on Obtaining an IND Application Acceptance Notice for the Innovative Drug HSK39004 Inhalation Suspension
Haisco Pharmaceutical Group: 002653 HiCisco Investor Relations Management Information 20240510
Haisco Pharmaceutical Group: Announcement on the cancellation of the pledge of some of the shares of the controlling shareholder
Haisco Pharmaceutical Group: Announcement on holding the 2023 online results briefing
Haisco Pharmaceutical Group: Announcement on Additional Provisional Proposals and Supplementary Notices for the 2023 Annual General Meeting of Shareholders
Haisco Pharmaceutical Group: Announcement on licensing and termination of the riluzole oral solution EXSERVAN project and preparation for impairment
Haisco Pharmaceutical Group: Announcement of Resolutions of the 14th Meeting of the Fifth Board of Directors
No Data